SISRAM MED Posts Interim Loss as Revenue Edges Higher
Stock News
Aug 19
SISRAM MED (01696) has released its interim results for the 2026 fiscal period, revealing a shift into the red on the bottom line. The company generated revenue of approximately $171.4 million, marking a 3.6% increase compared to the prior corresponding period.
Despite the top-line growth, the parent company shareholders recorded a loss of $1.155 million, a sharp reversal from the profit posted in the same period last year. The loss translates to a per-share deficit of 0.25 US cents, underscoring the earnings swing from profitability to a loss.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.